Journal ArticleDOI
Cardiac Resynchronization in Chronic Heart Failure
William T. Abraham,Westby G. Fisher,Andrew L. Smith,David B. Delurgio,Angel R. Leon,Evan Loh,Dusan Z. Kocovic,Milton Packer,Alfredo L. Clavell,David L. Hayes,Myrvin H. Ellestad,Robin J. Trupp,Jackie Underwood,Faith Pickering,Cindy Truex,Peggy McAtee,John C. Messenger +16 more
Reads0
Chats0
TLDR
Cardiac resynchronization results in significant clinical improvement in patients who have moderate-to-severe heart failure and an intraventricular conduction delay.Abstract:
Background Previous studies have suggested that cardiac resynchronization achieved through atrial-synchronized biventricular pacing produces clinical benefits in patients with heart failure who have an intraventricular conduction delay. We conducted a double-blind trial to evaluate this therapeutic approach. Methods Four hundred fifty-three patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec or more were randomly assigned to a cardiac-resynchronization group (228 patients) or to a control group (225 patients) for six months, while conventional therapy for heart failure was maintained. The primary end points were the New York Heart Association functional class, quality of life, and the distance walked in six minutes. Results As compared with the control group, patients assigned to cardiac resynchronization experienced an improvement in the distance walked in six minutes (+39 vs. +10 m, P=0.005), functional clas...read more
Citations
More filters
Journal ArticleDOI
Prediction of response to cardiac resynchronization therapy using simple electrocardiographic and echocardiographic tools
Hamid Reza Bonakdar,Mohammad Vahid Jorat,Amir Farjam Fazelifar,Abolfath Alizadeh,Nozar Givtaj,Niloofar Sameie,Anita Sadeghpour,Majid Haghjoo +7 more
TL;DR: In this paper, the authors predict response to cardiac resynchronization therapy (CRT) in patients with heart failure and intraventricular conduction delay using simple electrocardiographic and echocardiographic data.
Journal ArticleDOI
Guiding and optimization of resynchronization therapy with dynamic three-dimensional echocardiography and segmental volume–time curves: a feasibility study
Boudewijn J. Krenning,Tamas Szili-Torok,Marco M. Voormolen,Dominic A.M.J. Theuns,Luc Jordaens,Charles T. Lancée,Nico de Jong,Anton F. W. van der Steen,Folkert J. ten Cate,Jos R.T.C. Roelandt +9 more
TL;DR: To assess a new approach for guiding and hemodynamic optimization of resynchronization therapy, using three‐dimensional (3D) transthoracic echocardiography.
Journal ArticleDOI
Mid-term follow up of thromboembolic complications in left ventricular endocardial cardiac resynchronization therapy
TL;DR: Endocardial LV lead placement in patients with advanced heart failure is associated with thromboembolic risk, however, all but 1 patient had a subtherapeutic level of anticoagulation, and endocardialLV lead placement is not associated with aggravation of MR.
Journal ArticleDOI
A simplified technique for implantation of left ventricular epicardial leads for biventricular resynchronisation using video-assisted thoracoscopy (VATS)
S Gabor,Guenther Prenner,Andrae Wasler,Martin Schweiger,Karl Heinz Tscheliessnigg,Frejya Maria Smolle-Jüttner +5 more
TL;DR: Video-assisted thoracoscopy over two ports seems to be an excellent alternative procedure for epicardial lead implantation and produces good pacing results at a short intervention time and tolerable stress for the patients.
Journal ArticleDOI
Nonspecific intraventricular conduction delay: Definitions, prognosis, and implications for cardiac resynchronization therapy
Romain Eschalier,Romain Eschalier,Sylvain Ploux,Philippe Ritter,Michel Haïssaguerre,Kenneth A. Ellenbogen,Pierre Bordachar +6 more
TL;DR: Results from CRT are contradictory in this patient group, despite a seemingly neutral trend, and Guidelines recommending implantation of CRT devices in this group are based solely on analyses of subgroups with small sample sizes.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
Serge Cazeau,Christophe Leclercq,Thomas Lavergne,S Walker,Varma C,Cecilia Linde,Stéphane Garrigue,Lukas Kappenberger,G A Haywood,Massimo Santini,Bailleul C,Jean-Claude Daubert,Multisite Stimulation in Cardiomyopathies (Mustic) Study Investigators +12 more
TL;DR: In this article, transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle) were used to reduce ventricular asynchrony.
Journal Article
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure
Gordon H. Guyatt,Michael J. Sullivan,Penelope J. Thompson,Ernest L. Fallen,S. O. Pugsley,D W Taylor,Leslie B. Berman +6 more
TL;DR: It is concluded that the 6-minute walk is a useful measure of functional exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic heart failure.
Journal ArticleDOI
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II Losartan Heart Failure Survival Study as discussed by the authors showed an association between the angiotensin II antagonist losartan and an unexpected survival benefit in elderly heart-failure patients, compared with captopril, an ACE inhibitor.